↓ Skip to main content

Prognostic value of protein inhibitor of activated STAT3 in breast cancer patients receiving hormone therapy

Overview of attention for article published in BMC Cancer, January 2016
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
7 Dimensions

Readers on

mendeley
12 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Prognostic value of protein inhibitor of activated STAT3 in breast cancer patients receiving hormone therapy
Published in
BMC Cancer, January 2016
DOI 10.1186/s12885-016-2063-1
Pubmed ID
Authors

Sheau-Fang Yang, Ming-Feng Hou, Fang-Ming Chen, Fu Ou-Yang, Yang-Chang Wu, Chee-Yin Chai, Yao-Tsung Yeh

Abstract

Deregulated signal transducer and activator of transcription 3 (STAT3) signaling has been well documented in certain cancers. Alterations in specific negative regulators, such as protein inhibitor of activated STAT3 (PIAS3), may contribute to cancer development. The expression of total PIAS3 was determined in 100 paired cancerous and non-cancerous breast tissues by immunoblotting and was statistically analyzed along with the clinicopathological characteristics and overall survival of the patients. XTT, immunoblotting, and chromatin immunoprecipitation (Chip) were used to examine the biological effect of PIAS3 in breast cancer cells. Hormone therapy failed to improve the overall survival in patients presenting with increased PIAS3 expression. Ectopic PIAS3 overexpression increased the proliferation and expression of cyclin D1 in estrogen receptor (ER)-positive MCF-7 and T47D cells, but decreased those in ER-negative MDA-MB-231 and SKBR3 cells. Furthermore, PIAS3 overexpression attenuated cytotoxicity of tamoxifen and increased proliferation and cyclin D1 expression in MCF-7 cells. PIAS3 also decreased the binding of itself on the cyclin D1 promoter and this decreased binding was not affected by tamoxifen. PIAS3 may serve as a biomarker for predicting hormone therapy stratification, although it is limited to those breast cancer patients receiving hormone therapy.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 12 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 12 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 25%
Student > Bachelor 2 17%
Student > Doctoral Student 2 17%
Student > Ph. D. Student 2 17%
Other 1 8%
Other 2 17%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 6 50%
Neuroscience 1 8%
Agricultural and Biological Sciences 1 8%
Unspecified 1 8%
Chemistry 1 8%
Other 2 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 January 2016.
All research outputs
#3,238,299
of 6,978,736 outputs
Outputs from BMC Cancer
#1,165
of 3,160 outputs
Outputs of similar age
#147,691
of 313,280 outputs
Outputs of similar age from BMC Cancer
#53
of 180 outputs
Altmetric has tracked 6,978,736 research outputs across all sources so far. This one has received more attention than most of these and is in the 50th percentile.
So far Altmetric has tracked 3,160 research outputs from this source. They receive a mean Attention Score of 3.3. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 313,280 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 48th percentile – i.e., 48% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 180 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.